Program
13-valent pneumococcal vaccine
Also written as “13-valent pneumococcal conjugate vaccine”, “13-valent Pneumococcal Conjugate Vaccine” and “13vPnC”.
Its studies are mostly in Pneumococcal Infections · Pneumonia, Pneumococcal · Pneumonia · Influenza, Human · HIV Infections, led by 7 companies.
Drug page13-valent pneumococcal vaccine: every studyMany companies study it; this page follows only the 65 they lead. All 129 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 570 open or running | phase 4since Aug 27, 2008 | Sep 19, 2005 | none ahead |
| CanSino Biologicsits history only | 31 open or running | phase 3since Apr 8, 2021 | Sep 18, 2019 | Feb 15, 2027phase 3 · NCT07017777 |
| Beijing Minhai Biotechnologyits history only | 10 open or running | phase 4since Jan 8, 2024 | Jan 8, 2024 | none ahead |
| Fosun Pharma | 11 open or running | phase 3since Feb 26, 2023 | Feb 26, 2023 | none ahead |
| Sinovac Biotechits history only | 10 open or running | phase 1since Oct 13, 2021 | Oct 13, 2021 | none ahead |
| Walvax Biotechnologyits history only | 10 open or running | phase 3since Mar 31, 2016 | Mar 31, 2016 | none ahead |
| Wuhan BravoVaxits history only | 10 open or running | phase 1since Oct 24, 2022 | Oct 24, 2022 | none ahead |
Also a collaborator on its studies: Liaoning Chengda Biotechnology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Fosun Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 26, 2023First study: phase 3 study in Pneumococcal InfectionsFirst studyNCT05759520 · 1,800 enrolled · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A pneumococcal conjugate vaccine containing 13 different strains of the bacterium Streptococcus pneumoniae, used in children and studied in immunocompromised patients for the prevention of pneumococcal disease”NCIt, by rule
Studies
The one study Fosun Pharma leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05759520Pneumococcal Infections · China | 3 | Active, not recruiting | Jun 30, 2025 | 1,800 |
How it is read
Names in the registry
- “13-valent pneumococcal conjugate vaccine”, 23 entries
- “13-valent Pneumococcal Conjugate Vaccine”, 20 entries
- “13vPnC”, 9 entries
- “13-valent pneumococcal conjugate vaccine (13vPnC)”, 8 entries
- “PCV13”, 5 entries
Codes read as this program: PCV13I.
Conditions, from the studies’ own filings
- Pneumococcal Infections, 26 studies
- Pneumonia, Pneumococcal, 2 studies
- Pneumonia, 2 studies
- Influenza, Human, 2 studies
- HIV Infections, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.